«Eclampsia

Below is an extended Eclampsia patents listing. Click here to return to the Eclampsia main in depth entry.

Patents :
US Patent No.	Title
7335362	Methods of treating pre-eclampsia or eclampsia
7358257	Platelet ADP receptor inhibitors
7361186	Active body cooling with vasodilation to reduce body temperature
7361517	Real time method of detecting acute inflammatory conditions
7361661	8-quinolinxanthine and 8-isoquinolinxanthine derivatives as PDE 5 inhibitors
7361677	Polycyclic sulphamate compounds suitable for use as inhibitors of aromatase and/or sulphatase
7363076	Treatment of conditions through modulation of the autonomic nervous system
7365155	Immunoregulator
7368270	Human phospholipases
7368425	Cyclic peptides for modulating growth of neo-vessels and their use in therapeutic angiogenesis
7368438	Non-nucleotide compositions and method for inhibiting platelet aggregation
7354725	Kinase peptides and antibodies
7354581	Therapeutic combination of a VEGF antagonist and anti-hypertensive agent
7351585	Retroviral vector
7335648	Non-nucleotide composition and method for inhibiting platelet aggregation
7335650	Composition
7335680	Pyrrolidine derivatives as prostaglandin modulators
7342004	Thioether sulphamate steroids as steroid inhibitors and anti-cancer compounds
7342034	Fused heterocyclic compounds and analogs thereof, modulators of nuclear hormone receptor function
7344503	System and method for monitoring pre-eclamptic patients
7344892	Screening for gestational disorders
7345019	Modulation of excitable tissue function by peripherally administered erythropoietin
7345047	Substituted [1,2,3]triazolo[4,5-d]pyrimidines
7345178	Sirtuin modulating compounds
7368527	HADDE71 polypeptides
7368531	Human secreted proteins
7402313	Method for controlling preeclampsia and eclampsia
7402322	Methods of treatment for septic shock with urine extract
7405234	Bicyclic modulators of androgen receptor function
7405311	Antagonist of the magnesium binding defect as therapeutic agents and methods for treatment of abnormal physiological states
7407659	Methods of diagnosing pre-eclampsia or eclampsia
7408041	Polypeptides and antibodies derived from chronic lymphocytic leukemia cells and uses thereof
7410941	Methods for treatment of neurodegenerative conditions by peripherally administered erythropoietin
7410991	Pyrazolidinone compounds as ligands of the prostaglandin EP2 and/or EP4 receptors
7411051	Antibodies to HDPPA04 polypeptide
7415358	Molecular toxicology modeling
7399636	Diagnostic kit for predicting pregnancy outcome
7399596	Method for predicting pregnancy-induced hypertension
7396829	Nitric oxide enhancing diuretic compounds, compositions and methods of use
7375136	pH-dependent NMDA receptor antagonists
7378426	Fused heterotricyclic compounds as inhibitors of 17.beta.-hydroxysteroid dehydrogenase 3
7381699	Reagents and methods for smooth muscle therapies
7381734	Serine protease inhibitors
7381800	Antibodies to HBIMF63 polypeptide
7385036	Human tango 509 polypeptides
7387999	Simmondsin for use as angiogenesis inhibitor
7388027	Bicyclic compounds as modulators of androgen receptor function and method
7396659	Inhibitors of nitric oxide synthase to treat type 1 diabetes
7396663	Isolated polynucleotide encoding a G-protein coupled receptor
7417040	Fused tricyclic compounds as inhibitors of 17.beta.-hydroxysteroid dehydrogenase 3

Nothing in this website should be used in place of personal medical advice from your own qualified medical practitioner.  See User Agreement

Send comments and feedback to:
Peter Barfoot Managing Director, BioPortfolio Ltd.
UK Tel: (+44) 1300 321501
USA Voicemail and Fax: (+1) 415 680 2472

All rights reserved. All other trademarks recognized.

BioPortfolio Limited is registered in England & Wales at Wessex Barn, Dorchester Road, Frampton, Dorset, DT2 9NB, UK. No.3312883 VAT No. GB 744 6483 10

Copyright 1997-2008 - BioPortfolio Limited.